Exxel Pharma, Inc. | WebDisclosure

Basculer en Français

8607	Companies
141266	Keywords
77176	Articles
75485	Press releases

Home
Companies
Exxel Pharma, Inc.

BRIEF

published on 02/03/2025 at 15:05, 2 months 6 days ago

Exxel Pharma's EX937: A Promising Advance for Chronic Cough Treatment

EX937 Refractory Chronic Cough Pharmaceutical Development Phase 1/1b Study FAAH Enzyme
BRIEF

published on 02/03/2025 at 15:05, 2 months 6 days ago

EX937 d'Exxel Pharma : une avancée prometteuse pour le traitement de la toux chronique

EX937 Développement Pharmaceutique Toux Chronique Réfractaire Étude De Phase 1/1b Enzyme FAAH
PRESS RELEASE

published on 02/03/2025 at 15:00, 2 months 6 days ago

Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Exxel Pharma presents its EX937 development program targeting refractory chronic cough, a $11B market need. Phase 1/1b study in normal volunteers starts Q3/4 2025 with unique FAAH inhibition approach

Exxel Pharma Refractory Chronic Cough Phase 1/1b Study EX937 Development Program FAAH Inhibition
BRIEF

published on 01/31/2025 at 16:05, 2 months 9 days ago

Exxel Pharma to Join "New to Virtual Investor" Event

Exxel Pharma EX937 Neuronal Hypersensitivity Virtual Investor Webcast Event
BRIEF

published on 01/31/2025 at 16:05, 2 months 9 days ago

Exxel Pharma participera à l'événement « New to Virtual Investor »

Exxel Pharma EX937 Investisseur Virtuel Webcast De L'événement Hypersensibilité Neuronale
PRESS RELEASE

published on 01/31/2025 at 16:00, 2 months 9 days ago

Exxel Pharma to Participate in a "New to Virtual Investor" Segment
Exxel Pharma to participate in a live moderated video webcast on February 5, 2025, at 4:00 PM ET. CEO Soren Mogelsvang to discuss corporate overview and business outlook

Pharmaceutical Company Exxel Pharma Live Webcast Soren Mogelsvang Neuronal Hypersensitivity Disorders
BRIEF

published on 05/01/2024 at 16:05, 11 months 8 days ago

Exxel Pharma to Showcase in Virtual Investor Lunch Break

Exxel Pharma EX937 Virtual Investor Event Chronic Cough Treatment Pharmaceutical Development
BRIEF

published on 05/01/2024 at 16:05, 11 months 8 days ago

Exxel Pharma sera présent lors d'une pause déjeuner virtuelle pour les investisseurs

Exxel Pharma EX937 Événement Virtuel Pour Les Investisseurs Traitement De La Toux Chronique Développement Pharmaceutique
PRESS RELEASE

published on 05/01/2024 at 16:00, 11 months 8 days ago

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity
Soren Mogelsvang, PhD, CEO of Exxel Pharma, to present at Virtual Investor Lunch Break event discussing Exxel opportunity on May 8th. EX937 development updates

Exxel Pharma EX937 Virtual Investor Lunch Break Chronic Cough Treatment Soren Mogelsvang
PRESS RELEASE

published on 01/25/2024 at 16:00, 1 year 2 months ago

Exxel Pharma Provides Business Overview and Upcoming Milestones
Exxel Pharma provided a business overview of its lead program, EX937, an innovative small molecule for treating refractory chronic cough, a condition currently with no FDA-approved therapies. The program demonstrates a differentiated approach with preclinical efficacy and safety, aiming for potential value-driving milestones in 2024 and addressing a large underserved market. The company expects EX937 to have a significant impact on improving the quality of life for adults suffering from chronic cough, with potential broad clinical applications and commercial opportunities.

Exxel Pharma EX937 Refractory Chronic Cough FAA Enzyme Neuronal Hypersensitivity

Accesswire

Published on 04/10/2025 at 02:30, 3 hours 30 minutes ago

Star Copper Completes Non-Brokered Private Placement for Proceeds of $2,500,000
Published on 04/10/2025 at 01:40, 4 hours 20 minutes ago

RRS Gather Round Conference Presentation
Published on 04/09/2025 at 23:30, 6 hours 30 minutes ago

AirIQ Announces Major Customer Win Accelerating Growth in Recurring Revenue
Published on 04/09/2025 at 22:17, 7 hours 43 minutes ago

Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Published on 04/09/2025 at 22:05, 7 hours 55 minutes ago

Amdocs Announces Q3F25 Investor Conference Schedule

View all ACCESSWIRE

EQS Group

Published on 04/10/2025 at 04:55, 1 hour 5 minutes ago

CO2Coin one of the most successful crypto investments of the coming decades.
Published on 04/09/2025 at 20:20, 9 hours 40 minutes ago

Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences
Published on 04/09/2025 at 20:18, 9 hours 42 minutes ago

EQS-Adhoc: VOLKSWAGEN AKTIENGESELLSCHAFT: Volkswagen AG publishes preliminary key figures for the financial statements as of March 31, 2025
Published on 04/09/2025 at 19:08, 10 hours 51 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/09/2025 at 18:45, 11 hours 15 minutes ago

EUROPLASMA: Précisions dans le cadre du projet de reprise de la Fonderie de Bretagne

Les Echos

Published on 04/09/2025 at 18:59, 11 hours ago

Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:59, 11 hours ago

Descriptif du programme de rachat d'actions 2025-2026
Published on 04/09/2025 at 18:57, 11 hours 2 minutes ago

Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 18:57, 11 hours 2 minutes ago

Compte-rendu de l'Assemblée Générale Mixte du 9 avril 2025
Published on 04/09/2025 at 17:45, 12 hours 15 minutes ago

COGELEC : Résultats annuels 2024 et Chiffre d’affaires du 1 er trimestre 2025.

View all LES ECHOS COMFI WIRE